Latest filings (excl ownership)
8-K
Candel Therapeutics Announces Upcoming Presentations
25 Apr 24
10-K/A
2023 FY
Annual report (amended)
25 Apr 24
8-K
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
11 Apr 24
8-K
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
9 Apr 24
8-K
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
4 Apr 24
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
28 Mar 24
8-K
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
6 Mar 24
424B5
Prospectus supplement for primary offering
13 Feb 24
8-K
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
13 Feb 24
8-K
Departure of Directors or Certain Officers
12 Jan 24
8-K
Other Events
3 Jan 24
8-K
Departure of Directors or Certain Officers
14 Dec 23
8-K
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Pancreatic Cancer
12 Dec 23
8-K
Cost Associated with Exit or Disposal Activities
28 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
21 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
9 Nov 23
8-K
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
6 Nov 23
8-K
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
6 Nov 23
8-K
Regulation FD Disclosure
18 Oct 23
8-K
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
26 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
29 Jun 23
8-K
Based on forthcoming completion of patient enrollment and duration of follow-up in Cohort 2 from the phase 2 trial in late-stage NSCLC
13 Jun 23
8-K
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
8 Jun 23
ARS
2022 FY
Annual report to shareholders
23 May 23
DEF 14A
Definitive proxy
23 May 23
8-K
Regulation FD Disclosure
19 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
11 May 23
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
9 May 23
8-K
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Non-Small Cell Lung Cancer
17 Apr 23
S-8
Registration of securities for employees
30 Mar 23
10-K
2022 FY
Annual report
30 Mar 23
8-K
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
30 Mar 23
8-K
Regulation FD Disclosure
22 Feb 23
Latest ownership filings
3
Charles Schoch
19 Jan 24
4
Seshu Tyagarajan
30 Nov 23
4
Paul Peter Tak
30 Nov 23
4
William Garrett Nichols
30 Nov 23
4
Francesca Barone
30 Nov 23
4
Jason Amello
30 Nov 23
4
Paul Peter Tak
28 Nov 23
4
Seshu Tyagarajan
28 Nov 23
4
William Garrett Nichols
28 Nov 23
4
Francesca Barone
28 Nov 23
4
Jason Amello
28 Nov 23
4
Renee Gaeta
29 Jun 23
4
Diem Nguyen
29 Jun 23
4
Paul B Manning
29 Jun 23
4
Christopher Martell
29 Jun 23
4
Edward J. Benz JR
29 Jun 23
4
JOSEPH C PAPA
29 Jun 23
4
Estuardo Aguilar-Cordova
29 Jun 23
4
Gary J. Nabel
29 Jun 23
4
Nicoletta Loggia
9 Jun 23
3
Nicoletta Loggia
9 Jun 23
4
Paul Peter Tak
2 May 23
4
Seshu Tyagarajan
2 May 23
4
William Garrett Nichols
2 May 23
4
Francesca Barone
2 May 23
4
Jason Amello
2 May 23
4/A
Christopher Martell
17 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
4
Francesca Barone
12 Dec 22
4
JOSEPH C PAPA
12 Dec 22
4
Christopher Martell
12 Dec 22
4
Paul Peter Tak
12 Dec 22
4
Seshu Tyagarajan
12 Dec 22
4
Jason Amello
12 Dec 22
4
Jason Amello
30 Nov 22
4
Paul Peter Tak
30 Nov 22
4
Francesca Barone
30 Nov 22
4
William Garrett Nichols
30 Nov 22
4
Seshu Tyagarajan
30 Nov 22
4
Estuardo Aguilar-Cordova
17 Oct 22